Evaluation of Lenaliodomide as a Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for high-risk multiple Myeloma
|Effective start/end date||2/1/08 → 1/1/13|
- NATIONAL MARROW DONOR PROGRAM
- CELGENE CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.